Document:

<Page>

                                                                 Exhibit 10.61

             SUMMARY OF BOARD OF DIRECTORS COMPENSATION ARRANGEMENT

         All of the members of the Board of Directors (each, a "Director" and
collectively, the "Board of Directors") of Genaissance Pharmaceuticals, Inc.
(the "Company") are reimbursed for expenses in connection with attendance at the
Company's Board of Directors and committee meetings. Each non-employee Director,
other than Dr. Jurgen Drews, receives $20,000 per year in the form of equity of
the Company in consideration for serving on the Board of Directors and $1,500
for attendance at each Board of Directors meeting. Dr. Drews receives $60,000
per year plus a non-accountable expense allowance of $30,000 per year in
consideration for serving as chairman of the Board of Directors. The members of
the Company's Audit Committee (the "Audit Committee") also each receive $1,500
for each committee meeting attended in person. In addition, the chair of the
Audit Committee is paid an annual cash retainer fee of $7,500. The members of
each of the Company's Nominating and Corporate Governance Committee and
Compensation Committee, except for Dr. Drews, each receive $1,000 for each
committee meeting attended in person. In the event that any of the meetings of
the Board of Directors or any committee thereof are held telephonically, each
Director who participates in such telephonic meeting is paid $500 per meeting so
long as the meeting lasts longer than thirty minutes.

         Our non-employee Directors are eligible to participate in our 2000
Amended and Restated Equity Incentive Plan, as amended, which we sometimes refer
to as our "equity incentive plan." On October 1 of each year, each non-employee
Director receives an automatic grant of an option to purchase 10,000 shares of
our common stock. In addition, upon initial election to the Board of Directors,
each non-employee Director receives an automatic grant of an option to purchase
20,000 shares of our common stock, except for our chairman, Dr. Drews, who
received an initial grant of an option to purchase 25,000 shares of our common
stock. The stock options granted upon initial election and the stock options
granted annually become exercisable each quarter over a period of four years, so
long as the non-employee Director continues to serve on the Board of Directors.
The stock options have a term of ten years and an exercise price equal to the
closing price per share of our common stock as reported by the NASDAQ Stock
Market on the date of grant.<Page>

                                                                   Exhibit 10.62

             COMPENSATION OF NAMED EXECUTIVE OFFICERS OF THE COMPANY

As of March 15, 2005, the following represents the compensation of the Company's
named executive officers:

<Table>
<Caption>
                                                              2005 COMPENSATION
------------------------------------------------------------------------------------------------------------
                                                               SHARES UNDERLYING       SHARES UNDERLYING
NAMED                                       ANNUAL SALARY       RESTRICTED STOCK     STOCK OPTIONS GRANTED
EXECUTIVE OFFICER                                             GRANTED IN 2005 (1)          IN 2005(2)
------------------------------------------------------------------------------------------------------------
<S>                                         <C>               <C>                    <C>
Kevin Rakin
     President and Chief Executive             $349,400            35,000 (3)             135,000(4)
     Officer
------------------------------------------------------------------------------------------------------------
Gerald F. Vovis, Ph.D.
    Executive Vice President and Chief
    Technology Officer                         $230,000            20,000 (5)              60,000(6)
------------------------------------------------------------------------------------------------------------
Richard S. Judson, Ph.D.
    Senior Vice President and                  $220,000            25,000 (7)              85,000(8)
     Chief Scientific Officer
------------------------------------------------------------------------------------------------------------
Ben D. Kaplan
    Senior Vice President, Chief               $220,000            25,000 (9)              60,000(10)
    Financial Officer and Secretary
------------------------------------------------------------------------------------------------------------
Carl Balezentis, Ph.D.
    Senior Vice President and                  $157,500           25,000 (11)              60,000(12)
    President of Lark Technologies, Inc.

------------------------------------------------------------------------------------------------------------
</Table>

(1) Each of the restricted stock grants listed above were granted pursuant to
the Company's 2000 Amended and Restated Equity Incentive Plan, as amended, and
vests on February 17, 2006.

(2) Each of the stock options listed above were issued pursuant to the Company's
2000 Amended and Restated Equity Incentive Plan, as amended, has an exercise
price of $2.20 per share and vests quarterly over four years.

(3) Mr. Rakin's restricted stock was granted in accordance with the terms of
that certain Restricted Stock Agreement that he entered into with the Company on
January 7, 2005.

(4) Mr. Rakin's stock options were granted in accordance with the terms of that
certain Incentive Stock Option Agreement that he entered into with the Company
on January 7, 2005, a form of which is filed as an exhibit to the Company's
Quarterly Report on Form 10-Q as filed with the Securities and Exchange
Commission ("SEC") on November 15, 2004.

(5) Dr. Vovis's restricted stock was granted in accordance with the terms of
that certain

<Page>

                                                                   Exhibit 10.62

Restricted Stock Agreement that he entered into with the Company on January 7,
2005.

(6) Dr. Vovis's stock options were granted in accordance with the terms of that
certain Incentive Stock Option Agreement that he entered into with the Company
on January 7, 2005, a form of which is filed as an exhibit to the Company's
Quarterly Report on Form 10-Q as filed with the SEC on November 15, 2004.

(7) Dr. Judson's restricted stock was granted in accordance with the terms of
that certain Restricted Stock Agreement that he entered into with the Company on
January 7, 2005.

(8) Dr. Judson's stock options were granted in accordance with the terms of that
certain Incentive Stock Option Agreement that he entered into with the Company
on January 7, 2005, a form of which is filed as an exhibit to the Company's
Quarterly Report on Form 10-Q as filed with the SEC on November 15, 2004.

(9) Mr. Kaplan's restricted stock was granted in accordance with the terms of
that certain Restricted Stock Agreement that he entered into with the Company on
January 7, 2005.

(10) Mr. Kaplan's stock options were granted in accordance with the terms of
that certain Incentive Stock Option Agreement that he entered into with the
Company on January 7, 2005, a form of which is filed as an exhibit to the
Company's Quarterly Report on Form 10-Q as filed with the SEC on November 15,
2004.

(11) Dr. Balezentis's restricted stock was granted in accordance with the terms
of that certain Restricted Stock Agreement that he entered into with the Company
on January 7, 2005.

(12) Dr. Balezentis's stock options were granted in accordance with the terms of
that certain Incentive Stock Option Agreement that he entered into with the
Company on January 7, 2005, a form of which is filed as an exhibit to the
Company's Quarterly Report on Form 10-Q as filed with the SEC on November 15,
2004.<PAGE>

                                                                   Exhibit 10.63

                            WAIVER AND ACKNOWLEDGMENT

      THIS WAIVER AND ACKNOWLEDGMENT, dated as of November 18, 2004, is by and
between Genaissance Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), and RAM Trading, Ltd., a Cayman Islands exempted company (the
"Investor"). Capitalized terms used herein without definition have the
respective meanings given them in the Series A Preferred Stock Purchase
Agreement, dated as of October 29, 2003, by and between the Company and the
Investor (the "Purchase Agreement").

                                   BACKGROUND

       A.     Pursuant to the Purchase Agreement, the Investor acquired from the
              Company 270,000 shares of Series A Preferred Stock and a warrant
              to purchase an additional 190,000 shares of Series A Preferred
              Stock.

       B.     The Purchase Agreement provides the Investor, as a holder of
              Series A Preferred Shares, with certain notice and contractual
              pre-emptive rights in the event the Company proposes to issue any
              Offered Securities.

       C.     The Certificate of Designations of the Series A Preferred Stock of
              the Company filed with the Secretary of State of the State of
              Delaware on October 29, 2003 (the "Certificate of Designations")
              provides the Investor, as a holder of Series A Preferred Shares,
              with certain (i) mandatory redemption rights in the event the
              Company issues any shares of Common Stock (or any securities
              convertible into or exchangeable for Common Stock) for a per share
              purchase price of less than $2.25 (as adjusted for any stock
              split, stock dividend, recapitalization or otherwise), other than
              certain specified issuances and (ii) voting rights with respect to
              the incurrence by the Company of Indebtedness (as defined in the
              Certificate of Designations).

       D.     The Company is contemplating an equity financing to be consummated
              on or prior to November 19, 2004, pursuant to which the Company
              would issue and sell between $4.0 million and $6.0 million worth
              of shares of Common Stock (the "Shares") at a per share purchase
              price not less than $1.67 (the "Financing").

       E.     The stock purchase agreement and any other transaction documents
              that will relate to the Financing are collectively referred to
              herein as the "Transaction Documents." In addition to providing
              for the issuance and sale by the Company of the Shares, the
              Transaction Documents will provide for the issuance by the Company
              to purchasers in the Financing of Warrants to purchase up to a
              number of shares of Common Stock equal to the number of Shares to
              be sold in the Financing (collectively, "Warrants") at a per share
              exercise price equal to the price paid per share of such Shares.

       F.     The Company and the Investor desire to set forth their
              understanding and agreement with respect to certain provisions of
              the Purchase Agreement and the Certificate of Designations, in
              order to enable the Company to proceed with the Financing.

     With respect to the issuance by the Company of the (i) Shares, (ii)
Warrants and (iii) shares of Common Stock issuable upon exercise of the Warrants
pursuant to the Transaction Documents (each, an "Issuance"), the parties hereto
acknowledge and agree as follows:

       1. PURCHASE AGREEMENT. In accordance with Section 9.2 of the Purchase
Agreement, any notice or contractual pre-emptive rights of the Investor pursuant
to Section 5.5 of the Purchase Agreement shall be waived and shall not apply to
an Issuance.

<PAGE>

       2. CERTIFICATE OF DESIGNATIONS. The Investor, as the holder of at least
66? percent of the shares of Series A Preferred Stock outstanding, hereby
elects, agrees and acknowledges that:

            (a) the mandatory redemption required by Section 6(c)(ii) of the
Certificate of Designations shall not apply to any Issuance;

            (b) any violation by the Company of Section 3(b)(vi) of the
Certificate of Designations from and after October 29, 2003 through September
30, 2004 is hereby waived;

            (c) from and after September 30, 2004, the amount of the
Indebtedness which the Company may incur under Section 3(b)(vi)(A) of the
Certificate of Designations without the prior consent of the Investor shall be
increased from $7.0 million to $9.0 million; and

            (d) as soon as practicable after the date hereof, the Company shall
file a certificate of amendment to the Certificate of Designations to the effect
set forth in provision (c) above, provided that any such certificate of
amendment shall be subject to the approval of the Investor.

       3. COUNTERPARTS; FACSIMILE SIGNATURES. This Waiver and Acknowledgment may
be executed in two or more counterparts (including by facsimile signature), each
of which shall be deemed an original but all of which, when taken together,
shall be considered one and the same agreement.

      4. SUCCESSORS AND ASSIGNS. The terms and conditions of this Waiver and
Acknowledgment shall inure to the benefit of and be binding upon the respective
successors and assigns of the Company and the Investor (including transferees of
any Series A Preferred Shares of the Investor or any securities into which such
Series A Preferred Shares are convertible).

       5. GOVERNING LAW. This Waiver and Acknowledgment shall be governed by,
and construed in accordance with, the laws of the State of Delaware.

      6. EFFECT OF WAIVER. Except as expressly set forth herein, the execution,
delivery and performance of this Waiver and Acknowledgment shall not operate as
a waiver or amendment of any right, power or remedy of the Investor under the
Purchase Agreement or Certificate of Designations. Nothing herein shall be
deemed to entitle the Company to a waiver or consent in the future with respect
to any condition, obligation, covenant or agreement contained in the Purchase
Agreement, Registration Rights Agreement or Certificate of Designations.

      7. EXPIRATION OF WAIVER. This Waiver and Acknowledgment shall be deemed to
only apply to a Financing that is consummated (i.e., money is transferred from
purchasers of Common Stock to the Company) on or prior to 11:59 p.m. (New York
City time) on November 19, 2004 (the "Expiration Time"). Accordingly, if such
Financing is consummated after the Expiration Time, then this Waiver and
Acknowledgment shall be deemed null and void in all respects.

                     [REMAINDER OF PAGE INTENTIONALLY BLANK]

<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Waiver and
Acknowledgment to be duly executed by their respective authorized signatories as
of the date first above written.

                                        GENAISSANCE PHARMACEUTICALS, INC.

                                        By: /s/ Ben D. Kaplan
                                            -----------------------------
                                            Ben D. Kaplan
                                            Chief Financial Officer

                                        RAM TRADING, LTD.

                                        By: /s/ Jim Park
                                            -----------------------------
                                            Name:
                                            Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]